Although many association studies of polymorphisms in candidate genes with the clinical outcomes of breast cancer patients receiving adjuvant tamoxifen therapy have been reported, genetic factors determining individual response to tamoxifen are not fully understood. To identify genetic polymorphisms associated with clinical outcomes of patients with tamoxifen treatment, we conducted a genome-wide association study (GWAS). We studied 462 Japanese patients with hormone receptor-positive, invasive breast cancer receiving adjuvant tamoxifen therapy. Of them, 240 patients were analyzed by genome-wide genotyping using the Illumina Human610-Quad BeadChips, and two independent sets of 105 and 117 cases were used for replication studies. In the GWAS, we detected significant associations with recurrence-free survival at 15 singlenucleotide polymorphisms (SNPs) on nine chromosomal loci (1p31, 1q41, 5q33, 7p11, 10q22, 12q13, 13q22, 18q12 and 19p13) that satisfied a genome-wide significant threshold (log-rank P 5 2.87 3 10 29 -9.41 3 10 28 ). Among them, rs10509373 in C10orf11 gene on 10q22 was significantly associated with recurrencefree survival in the replication study (log-rank P 5 2.02 3 10
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INTRODUCTION
Tamoxifen has been the gold standard for endocrine treatment of patients with estrogen receptor (ER)-positive breast cancers. However, 30 -50% of patients with adjuvant tamoxifen therapy experience relapse and subsequently die of the disease (1,2), indicating individual differences in responsiveness to tamoxifen. Tamoxifen is metabolized to the highly active metabolites, 4-hydroxytamoxifen and 4-hydroxy-N-desmethyltamoxifen (endoxifen). It is reported that these metabolites are the active therapeutic moieties, having 100-fold greater affinity to ER and 30-100-fold greater potency in suppressing estrogen-dependent cell proliferation than those of tamoxifen (3 -5) . Inter-individual differences in the formation and elimination of these active metabolites could be one of the important factors affecting variability in the response to tamoxifen. Most previous reports focused on the genes involved in the pharmacokinetics of tamoxifen and its metabolites seek genetic variations which determine the individual response to tamoxifen. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6), which is the key enzyme responsible for the generation of endoxifen, is thought to be the most promising predictor of plasma concentration of endoxifen and clinical efficacy of tamoxifen in breast cancer patients (6) (7) (8) (9) (10) (11) (12) (13) (14) . Schroth et al. (15) recently reported outstanding results in 1325 breast cancer patients, providing sufficiently powered evidence for an association between CYP2D6 genotype and clinical outcomes in patients treated with tamoxifen in the adjuvant setting. Besides CYP2D6, several genes, such as CYP2C19, CYP3A5, sulfotransferase 1A1 (SULT1A1), UDPglucuronosyltransferase 2B15 (UGT2B15) and ATP-binding cassette sub-family C member 2 (ABCC2), were reported as possible candidates associated with the clinical outcomes of tamoxifen therapy (7, 10, 14, 16) ; however, associations of these candidate genes have not yet been sufficiently validated. Therefore, individual differences in responsiveness to tamoxifen still remain, even if the effects of genetic polymorphisms of CYP2D6 were considered, suggesting the existence of other genetic factor(s).
In this study, to identify responsible loci for the clinical outcomes of tamoxifen therapy, we performed a genome-wide association study (GWAS) by genotyping over 610 000 single-nucleotide polymorphisms (SNPs) and identified the novel locus containing chromosome 10 open-reading frame 11 (C10orf11) gene associated with recurrence-free survival in the breast cancer patients treated with tamoxifen.
RESULTS

Patient characteristics
We recruited 462 Japanese patients with breast cancer receiving adjuvant tamoxifen therapy. Table 1 summarizes the characteristics of all of these patients who were pathologically diagnosed to have a hormone receptor-positive, invasive breast cancer. Their median age at the time of surgery was 51 years old (range, 27-84 years), the median follow-up period was 6.8 years (range, 0.6-23.5 years) and the median tamoxifen treatment period was 4.8 years (range, 0.6 -6.3 years). Among the characteristics listed in Table 1 , tumor size and nodal status showed significant associations with the recurrence-free survival [P ¼ 0.000215; hazard ratio (HR), 1.71; 95% confidence interval (CI), 1.29 -2.27; and P ¼ 0.0138; HR, 1.83; 95% CI, 1.14-3.09, respectively] in the Cox proportional hazards analysis, whereas the other factors were not associated with recurrence-free survival (Supplementary Material, Table S1 ).
Genome-wide association and replication studies
We conducted a GWAS of recurrence-free survival of 240 Japanese patients with breast cancer who received tamoxifen monotherapy using Illumina Human610-Quad BeadChips. After the standard quality control, association analysis was performed for 470 796 SNPs by the trend log-rank test. We generated a quantile -quantile plot (Supplementary Material, Fig. S1 ) and obtained the genomic control inflation factor (l GC ) of 1.023, indicating a low possibility of false-positive associations resulting from population stratification. We detected significant associations with recurrence-free survival at 15 SNPs in nine genetic regions (1p31, 1q41, 5q33, 7p11, 10q22, 12q13, 13q22, 18q12 and 19p13) that satisfied a genome-wide significant threshold of P , 1.06 × 10
27
( Fig. 1) . To further validate the results of GWAS, we carried out a replication study using an independent 105 breast cancer patients. We genotyped 9 of the 15 SNPs because 6 of them were highly linked to another SNP (r 2 . 0.80; Supplementary Material, Table S2 ). We found that rs10509373 in C10orf11 gene on 10q22 was significantly associated with recurrence-free survival in the replication stage (log-rank P ¼ 4.18 × 10
24
; Table 2 and Fig. 2 ). The associations of the other SNPs were not replicated (Supplementary Material, Table S2 ). Furthermore, a combined result of the GWAS and first replication study strongly suggested an association of this locus with recurrence-free survival in breast cancer patients treated with tamoxifen (log-rank P ¼ 2.19 × 10 210 ). We also genotyped rs10509373 using additional 117 samples, which include the patients receiving tamoxifen after chemotherapy and observed a significant association (log-rank P ¼ 1.86 × 10
22
). A combined P-value of all samples was 2.19 × 10
210
, suggesting the significant association with recurrence-free survival in breast cancer patients treated with tamoxifen ( Fig. 2 and Supplementary Material, Table S3 ). In Cox proportional hazards analysis, C10orf11 genotype (rs10509373) was an independent indicator of the recurrencefree survival after adjustment for tumor size and nodal status (P ¼ 6.28 × 10
28
; Table 2 ). The adjusted HRs of rs10509373 C allele was 4.51 (95% CI, 2.72 -7.51), suggesting that C allele was a risk allele for breast cancer recurrence.
To further identify SNPs associated with recurrence-free survival in patients receiving tamoxifen therapy, we genotyped 130 tag SNPs for fine mapping on chromosome 10q22 (Chr. 10: 77.35 -78.70 Mb) where the most significant association with the recurrence-free survival was observed ( Fig. 3 and Supplementary Material, Table S4 ). Although no SNPs showed a stronger association than the landmark SNP, rs10509373, fine mapping of this region indicated that a 172-kb linkage disequilibrium (LD) block (77.67 -77.84 Mb) including C10orf11 was likely to contain the genetic variant(s) associated with recurrence-free survival in patients receiving tamoxifen therapy.
Combination analysis with previously identified gene loci
As we previously identified significant associations of CYP2D6 and ABCC2 rs3740065 genotypes with recurrencefree survival in patients treated with tamoxifen among the patients receiving tamoxifen monotherapy (Supplementary Material, Table S5 ) (7), we investigated a combined effect of C10orf11 genotype in addition to CYP2D6 and ABCC2 genotypes on the recurrence-free survival by classifying the 345 patients into 6 groups (0, 1, 2, 3, 4 and 5 risk allele groups) according to the number of risk alleles of the three genes. Kaplan -Meier analysis revealed the number of risk alleles of these three genes to have cumulative effects on recurrencefree survival (log-rank P ¼ 2.24 × 10
212
; Fig. 4 ). In the Cox proportional hazards analysis of 345 patients, the CYP2D6 and ABCC2 genotypes showed similar associations with recurrence-free survival to those in previous analysis of 282 patients (P ¼ 1.99 × 10 24 and 8.51 × 10 24 , respectively; Supplementary Material, Table S6) (7). In the multivariate analysis, rs10509373 in C10orf11 still showed a significant association even after adjustment of CYP2D6 and ABCC2 genotypes in addition to tumor size and nodal status (P ¼ 4.74 × 10
27
; Supplementary Material, Table S6 ), indicating that rs10509373 is an independent risk factor of breast cancer recurrence. Furthermore, combined analysis of C10orf11, CYP2D6 and ABCC2 revealed that genotypes of the three genes have cumulative effects on recurrence-free survival (P ¼ 2.28 × 10 212 ), and adjusted HR for risk of recurrence computed for patients carrying three or more risk alleles increased from 6.51-fold (three risk alleles) to 119.51-fold (five risk alleles) compared with those carrying one risk allele (Supplementary Material, Table S6 ). In the subgroup analysis of menopausal status, we identified the significant associations in both subgroups of pre-and postmenopausal patients, although the stronger association was observed in postmenopausal group than in the premenopausal patients (Supplementary Material, Table S7 ).
DISCUSSION
This study represents the first GWAS which attempts to identify genetic variants associated with clinical outcomes of tamoxifen therapy and successfully revealed that a marker SNP, rs10509373, on chromosome 10q22 was significantly associated with recurrence-free survival in 462 Japanese patients with breast cancer receiving tamoxifen monotherapy. Furthermore, combined analysis of this SNP with previously identified predictors, CYP2D6 and ABCC2, revealed that the number of risk alleles of the three genes have cumulative effects on recurrence-free survival in tamoxifen-treated breast cancer patients.
The most significantly associated SNP in this study, rs10509373 (combined P ¼ 1.26 × 10 210 ), is located in a 172-kb LD block which contains the 3 ′ region of C10orf11 It is reported that C10orf11 region overlaps with ultraconserved elements (UCEs), perfectly constrained elements between the human, mouse and rat genomes (17) (18) (19) . Their functional roles have not been completely elucidated yet; however, UCEs are thought to possess some essential functional properties. It is reported that paired box 2, encoded by PAX2 gene on 10q24, which regulates ERBB2 transcription and is involved in acquiring tamoxifen resistance (20) , and special AT-rich sequence-binding protein-1 encoded by SATB1 gene on 3p23, which delineates epigenetic modification and is associated with breast tumor growth and metastasis (21) , are located in the UCE-rich regions (17) . We further examined the association of pharmacokinetic data with C10orf11 genotype; however, no significant difference was observed between C10orf11 genotype and plasma levels of endoxifen and 4-hydroxytamoxifen in 98 breast cancer patients taking 20 mg/day tamoxifen (Supplementary Material, Fig. S2 ). According to our gene expression database (in-house), the C10orf11 transcript is expressed in breast cancer cells in clinical tissues. We examined the effects of rs10509373 on the expression levels of C10orf11 in peripheral blood mononuclear cells and brain using a public database SNPExpress (22) . However, no significant associations were observed (P ¼ 0.63 and 0.93, respectively) possibly because of the quite low expression of C10orf11 in these tissues. The association of C10orf11 genotype was significant in the second replication samples, which include the patients receiving tamoxifen alone after chemotherapy (Table 2) ; however, neither CYP2D6 nor ABCC2 genotypes were significantly associated with clinical outcomes in the second replication samples as shown in our previous study (Supplementary Material, Table S5 ) (23) . These lines of evidence might suggest that C10orf11 is involved in acquiring tamoxifen resistance or determining the characteristics of breast cancer, although further functional analysis will be needed to clarify the biological mechanisms which could have effects on the clinical outcomes of breast cancer patients receiving tamoxifen therapy. Several research groups focused on the genes involved in the pharmacokinetics of tamoxifen or its metabolites have investigated genetic variants of CYP2C19, CYP3A5, UGT2B15 and SULT1A1 as candidate genes associated with clinical outcomes of tamoxifen therapy (7, 10, 14, 16) . In our GWAS, no SNP in these candidate genes showed significant association with recurrence-free survival in patients treated with tamoxifen (log-rank P ¼ 3.14 × 10 22 -9.90 × 10
21
). According to the previous reports, the effect sizes of the above candidate genes were not so large, indicating that the sample size used in our study might not have enough power to detect associations of the SNPs with the tamoxifen efficacy.
Another group hypothesized that non-genomic steroid signaling and cross-talk with growth factor signaling pathways may contribute to the clinical outcomes of the patients treated with tamoxifen and reported that TC21 promoter polymorphism was significantly associated with an unfavorable tamoxifen treatment outcome; however, no significant association was observed at SNPs in TC21 gene in our GWAS (log-rank P ¼ 1.19 × 10 21 -9.98 × 10
) (24). The P-values of the SNPs in the ESR1, ESR2 and PGR genes, which encode ERa, ERb and progesterone receptor (PR), respectively, ranged from 1.33 × 10 22 to 9.88 × 10 21 , indicating no significant association.
In conclusion, our GWAS using 462 Japanese patients with breast cancer identified a new locus, containing the C10orf11 gene, associated with the clinical outcomes of breast cancer patients treated with tamoxifen. These findings provide new insights into personalized selection of hormonal therapy for the patients with breast cancer. However, large-scale replication study and further functional analysis are required to verify our results and to clarify their biological mechanisms which have effects on the clinical outcomes of patients receiving tamoxifen therapy.
MATERIALS AND METHODS
Patients
A total of 462 patients with primary breast cancer (including the 282 patients reported previously (6, 7) ) were recruited at Shikoku- * 10 collaborative group (Tokushima Breast Care Clinic, Yamakawa Breast Clinic, Shikoku Cancer Center, Kochi University Hospital, and Itoh Surgery and Breast Clinic), Kansai Rosai Hospital, Sapporo Breast Surgical Clinic and Sapporo Medical University Hospital. Of them, 240 patients who were recruited from September 2007 to September 2008 were used for a GWAS analysis, and the remaining 105 patients who were recruited from October 2008 to January 2010 were analyzed in a first replication study. All patients were Japanese women pathologically diagnosed with ER-positive and/or PR-positive, invasive breast cancer who received adjuvant tamoxifen monotherapy without any other treatments after surgical treatment between 1986 and 2008. In addition, we analyzed 117 patients who had been treated with tamoxifen monotherapy after receiving chemotherapy as the second replication set (23) . Data on primary breast cancer diagnosis or recurrence were confirmed from patients' medical record. Patients without recurrence were censored at the date of the last consultation. Recurrence-free survival time was defined as the time from surgical treatment to diagnosis of the recurrence of a breast cancer (locoregional, distant metastasis and contralateral breast events) or death. Patients received tamoxifen 20 mg/day for 5 years; tamoxifen was stopped at the time a recurrence was identified. ER and PR status were evaluated by enzyme immunoassay or immunohistochemistry. The cut-off for human epidermal growth factor receptor 2 overexpression was defined as 3+ immunohistochemical staining (25) . Nodal status was determined according to the International Union against Cancer tumor-node-metastasis classification. This study was approved by the Institutional Review Board in the Institute of Medical Science, The University of Tokyo (Tokyo, Japan), and written informed consent was obtained from all patients.
Genotyping and quality control
Genomic DNA was extracted from peripheral blood (n ¼ 424) or frozen breast tissue (n ¼ 38) using Qiagen DNA Extraction Kit (Qiagen, Valencia, CA, USA). In the GWAS, 240 patients were genotyped using the Illumina Human610-Quad BeadChip (Illumina, San Diego, CA, USA). Quality control of SNPs was achieved by excluding SNPs with low call rate (,99%) and SNPs with Hardy -Weinberg equilibrium P-value ,1.0 × 10
26
. SNPs with a minor allele frequency (MAF) ,0.01 were also excluded from further analysis. A total of 470 796 SNPs passed the filters and were further analyzed. We used multiplex polymerase chain reaction-based Invader Assay (Third Wave Technologies, Madison, WI, USA) on ABI PRISM 7900HT (Applied Biosystems, Foster City, CA, USA) for the replication study and fine mapping (26) . For fine mapping, tag SNPs were selected from the HapMap phase II JPT data (http://www.hapmap.org/) (27) with the following criteria: a pairwise r 2 . 0.80 and an MAF ≥ 0.01 using Haploview software (28) .
Genotyping of CYP2D6 and ABCC2 rs3740065 was performed using real-time Invader (Third Wave Technologies) and TaqMan assays (Applied Biosystems) as described previously (7, 29, 30) . To evaluate the effects of CYP2D6 alleles, we defined all of the decreased and null alleles (including * 4, * 5, * 10, * 14, * 21 and * 41, and gene-duplication alleles, * 10- * 10 and * 36- * 36) as allele 'V', and alleles of * 1 and duplicated * 1- * 1 as allele 'wt' as described previously (7) .
Statistical analysis
Recurrence-free survival curves were estimated using the Kaplan -Meier method. Statistical significance of a relationship between clinical outcomes and genetic polymorphism was assessed by the trend log-rank test. The value of l GC was calculated from the median of the trend log-rank test statistics (31) . Cox proportional hazards analysis was used to identify significant prognostic clinical factors and to test for an independent contribution of genetic factors to recurrencefree survival. To examine potential confounding, age was treated as a continuous variable, tumor size was treated as an ordinal variable, and the other covariates were treated as categorical variables. Genotypes were analyzed by assigning an ordinal score to each genotype (0 for homozygous non-risk alleles, 1 for heterozygous risk alleles and 2 for homozygous risk alleles). Combination effects were investigated by adding up the number of risk alleles of CYP2D6, ABCC2 and C10orf11 genes. All polymorphisms evaluated in this study were tested for deviation from Hardy -Weinberg equilibrium with the use of a x 2 -test. Statistical tests provided two-sided P-values, and a significance level of P , 0.05 was used. We used a significance level of P , 1.06 × 10 27 (0.05 of 470 796) in the GWAS and 5.56 × 10 23 (0.05 of 9) in the replication study to adjust multiple testing by the strict Bonferroni correction. Statistical analyses were carried out using SPSS (version 17.0, SPSS, Chicago, IL, USA) and the R statistical environment version 2.9.2 (http://www.r-project. org/).
